2017—venture funding goes into overdrive

Laura DeFrancesco is a Senior Editor at Nature Biotechnology. Licensing/collaboration Researcher Investor Value ($ millions) Deal description AstraZeneca Merck & Co. 8,500 Codevelop small-molecule PARP inhibitor Lynparza and MEK inhibitor selumetinib to treat multiple tumor types Assembly Biosciences Allergan 2,830 Exclusive, worldwide rights to orally… CONTINUE READING